Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Study Phase : Preclinical
Sponsor : Jazz Pharmaceuticals
Deal Size : $880.0 million
Deal Type : Acquisition
Jazz Pharmaceuticals Enters Agreement with Redx to Acquire KRAS Inhibitor Program
Details : Through the acquisition, Jazz Pharmaceuticals will have access to Redx Pharma KRAS inhibitor program for all clinical development, regulatory, manufacturing, and commercialization activities.
Brand Name : Undisclosed
Molecule Type : Small molecule
Upfront Cash : $10.0 million
February 07, 2024
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Sponsor : Jazz Pharmaceuticals
Deal Size : $880.0 million
Deal Type : Acquisition
Lead Product(s) : RXC007
Therapeutic Area : Oncology
Study Phase : Phase II
Sponsor : Jounce Therapeutics
Deal Size : Undisclosed
Deal Type : Termination
Termination of Proposed Business Combination of Jounce Therapeutics, Inc. and Redx Pharma plc
Details : Under the termination, Jounce Therapeutics will not merge with Redx. The business combination was supposed to aim the development of RXC007, a next-generation selective ROCK2 inhibitor, which is currently being assessed in a Phase 2a study in idiopathic ...
Brand Name : RXC007
Molecule Type : Small molecule
Upfront Cash : Undisclosed
April 03, 2023
Lead Product(s) : RXC007
Therapeutic Area : Oncology
Highest Development Status : Phase II
Sponsor : Jounce Therapeutics
Deal Size : Undisclosed
Deal Type : Termination
Lead Product(s) : RXC007
Therapeutic Area : Oncology
Study Phase : Phase II
Sponsor : Jounce Therapeutics
Deal Size : Undisclosed
Deal Type : Merger
Redx and Jounce Announce Recommended Business Combination
Details : Through the business combination, the combined group's priority will be the development of RXC007, a next-generation selective ROCK2 inhibitor, which is currently being assessed in a Phase 2a study in idiopathic pulmonary fibrosis (IPF).
Brand Name : RXC007
Molecule Type : Small molecule
Upfront Cash : Undisclosed
February 23, 2023
Lead Product(s) : RXC007
Therapeutic Area : Oncology
Highest Development Status : Phase II
Sponsor : Jounce Therapeutics
Deal Size : Undisclosed
Deal Type : Merger
Lead Product(s) : RXC007
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Redx Provides Progress Update on RXC007 Clinical Programm
Details : RXC007 is an oral, selective Rho Associated Coiled-Coil Containing Protein Kinase 2 (ROCK2) inhibitor which is currently being assessed in a Phase 2a study in idiopathic pulmonary fibrosis (IPF).
Brand Name : RXC007
Molecule Type : Small molecule
Upfront Cash : Not Applicable
February 09, 2023
Lead Product(s) : RXC007
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : A second arm of the trial, evaluating RXC004 in combination with the anti-PD-1 antibody nivolumab in patients with MSS mCRC, is expected to commence in the first half of 2022 once a recommended dose has been established in the ongoing Phase 1 dose escala...
Brand Name : RXC004
Molecule Type : Small molecule
Upfront Cash : Not Applicable
November 15, 2021
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Study Phase : Discovery
Sponsor : Jazz Pharmaceuticals
Deal Size : $420.0 million
Deal Type : Collaboration
Details : Under the terms of the collaboration agreement, Redx will be responsible for research and preclinical development activities up to Investigational New Drug (IND) submission.
Brand Name : Undisclosed
Molecule Type : Small molecule
Upfront Cash : $10.0 million
September 09, 2020
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Highest Development Status : Discovery
Sponsor : Jazz Pharmaceuticals
Deal Size : $420.0 million
Deal Type : Collaboration
Lead Product(s) : RXC006
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Preclinical
Sponsor : AstraZeneca
Deal Size : $377.0 million
Deal Type : Licensing Agreement
Redx Signs Out Licensing Agreement With Astrazeneca
Details : Under the terms of the exclusive global agreement, AstraZeneca will take RXC006 forward into clinical development, targeting fibrotic diseases including idiopathic pulmonary fibrosis (IPF).
Brand Name : RXC006
Molecule Type : Small molecule
Upfront Cash : Undisclosed
August 04, 2020
Lead Product(s) : RXC006
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Preclinical
Sponsor : AstraZeneca
Deal Size : $377.0 million
Deal Type : Licensing Agreement
Redx Pharma Provides Update on Its Phase 1/2a Clinical Trial of RXC004
Details : Recruitment to Redx's phase 1/2a clinical trial of RXC004, an oral porcupine inhibitor, has been halted in line with the policy of the five recruiting hospital centres in the UK.
Brand Name : Undisclosed
Molecule Type : Small molecule
Upfront Cash : Not Applicable
April 23, 2020
Lead Product(s) : RXC007
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Preclinical
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Preclinical data with compounds from Redx’s ROCK2 programme have demonstrated robust anti-fibrotic effects in a range of industry-standard in vivo models.
Brand Name : Undisclosed
Molecule Type : Undisclosed
Upfront Cash : Not Applicable
January 09, 2020
Lead Product(s) : RXC007
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Preclinical
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
LOOKING FOR A SUPPLIER?